Immutep Limited Market Cap ($45.10 Million)
Market Cap & Net Worth: Immutep Limited (YP1A)
Immutep Limited market cap. Immutep Limited (F:YP1A) has a market capitalization of $45.10 Million (€38.57 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #22118 globally and #1947 in its home market, demonstrating a -30.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immutep Limited's stock price €2.76 by its total outstanding shares 147372131 (147.37 Million). Also see how efficiently does Immutep Limited generate cash for how efficiently the company converts equity into cash flow.
Immutep Limited Market Cap History (2015–2026)
Immutep Limited market cap history from 2015 to 2026. Data shows change from $539.92 Million to $475.53 Million (-2.72% CAGR). Check today's stock price for Immutep Limited for real-time trading data and today's change.
Immutep Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immutep Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Immutep Limited annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2143.95x
Immutep Limited's market cap is 2143.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $270.81 Million | $2.63 Million | -$12.75 Million | 102.95x | N/A |
| 2019 | $267.05 Million | $139.78K | -$18.34 Million | 1910.51x | N/A |
| 2020 | $458.30 Million | $7.49 Million | -$13.47 Million | 61.22x | N/A |
| 2021 | $503.10 Million | $119.95K | -$29.90 Million | 4194.19x | N/A |
| 2022 | $272.22 Million | $247.66K | -$46.82 Million | 1099.17x | N/A |
| 2023 | $365.26 Million | $170.37K | -$39.90 Million | 2143.95x | N/A |
Competitor Companies of YP1A by Market Capitalization
Companies near Immutep Limited in the global market cap rankings as of November 3, 2026. Also see YP1A asset base for a full breakdown of the balance sheet.
Key companies related to Immutep Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Immutep Limited (2015–2026)
Market capitalization of Immutep Limited from 2015 to today. Between 2015 and today, Immutep Limited's market cap moved from $539.92 Million to $ 475.53 Million, with a yearly change of -2.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €475.53 Million | +9.52% |
| 2025 | €434.18 Million | +38.46% |
| 2024 | €313.57 Million | -14.15% |
| 2023 | €365.26 Million | +34.18% |
| 2022 | €272.22 Million | -45.89% |
| 2021 | €503.10 Million | +9.77% |
| 2020 | €458.30 Million | +71.61% |
| 2019 | €267.05 Million | -1.39% |
| 2018 | €270.81 Million | +26.49% |
| 2017 | €214.09 Million | -49.03% |
| 2016 | €420.00 Million | -22.21% |
| 2015 | €539.92 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Immutep Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.10 Million USD |
| MoneyControl | $45.10 Million USD |
| MarketWatch | $45.10 Million USD |
| marketcap.company | $45.10 Million USD |
| Reuters | $45.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more